Valuation: Alector, Inc.

Market Cap 214M 189M 178M 162M 303M 20.58B 306M 2.13B 827M 10.47B 805M 787M 34.08B P/E 2026 *
-2.23x
P/E 2027 * -2.9x
Enterprise Value -13.09M -11.51M -10.85M -9.9M -18.52M -1.26B -18.66M -130M -50.46M -639M -49.14M -48.07M -2.08B EV / Sales 2026 *
-1.19x
EV / Sales 2027 * -2.94x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -
1 day-4.95%
1 week+3.78%
Current month-15.04%
1 month-16.52%
3 months+7.26%
6 months-7.69%
Current year+23.08%
1 week 1.85
Extreme 1.85
2.05
1 month 1.79
Extreme 1.79
2.76
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Sell

Controller/Auditor

-3,625 0.0032%
9/3/26 Sell

Chief Financial Officer

-29,251 0.0262%
9/3/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
-4.95%+3.78%-39.24%-72.09% 226M
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-3.82%+34.21%+74.86% 59.55B
+2.71%-1.96%-13.79%+364.46% 25.84B
+0.81%+0.61%-0.49%-5.14% 24.73B
-1.05%+1.07%+21.45%-10.32% 20.87B
-1.70%-3.35%+146.86%+325.69% 15.32B
+2.15%-0.92%+48.93%+169.79% 14.06B
-0.43%-7.56%-20.10%+775.94% 13.12B
+0.04%-3.97%+20.23%+234.69% 11.85B
Average -0.58%-0.87%+25.31%+196.20% 25.98B
Weighted average by Cap. -0.72%-0.82%+35.04%+160.09%

Financials

2026 *2027 *
Net sales 10.97M 9.65M 9.1M 8.3M 15.52M 1.05B 15.64M 109M 42.3M 536M 41.19M 40.3M 1.74B 28.01M 24.64M 23.22M 21.19M 39.63M 2.69B 39.93M 279M 108M 1.37B 105M 103M 4.45B
Net income -97.52M -85.78M -80.86M -73.77M -138M -9.36B -139M -970M -376M -4.76B -366M -358M -15.5B -97.35M -85.63M -80.72M -73.64M -138M -9.34B -139M -969M -375M -4.76B -365M -358M -15.48B
Net Debt -227M -200M -189M -172M -322M -21.84B -324M -2.26B -877M -11.11B -854M -836M -36.16B -297M -261M -246M -225M -420M -28.49B -423M -2.95B -1.14B -14.5B -1.11B -1.09B -47.18B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-09-24 US$1.920 -4.95% 849,464
26-09-23 US$2.020 +0.50% 1,182,749
26-09-22 US$2.010 +4.15% 1,464,201
26-09-21 US$1.930 +1.05% 1,281,187
26-09-18 US$1.910 +3.24% 2,119,032
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.920USD
Average target price
3.100USD
Spread / Average Target
+61.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock